Nes­tle plans to ax hun­dreds of R&D staffers, shut­ter big der­ma­tol­ogy cam­pus

Three years af­ter Nes­tle paid $3.6 bil­lion to ac­quire full con­trol of Gal­der­ma, they’re tak­ing an ax to one of its big drug R&D cam­pus­es.

Billed as the largest R&D cam­pus de­vot­ed to der­ma­tol­ogy, the com­pa­ny is plan­ning to cut up to 450 of 550 re­search po­si­tions at Gal­der­ma’s Sophia An­tipo­lis R&D cen­ter near Nice as the com­pa­ny tran­si­tions to a new R&D mod­el that re­lies on more de­vel­op­ment part­ner­ships.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER